Phase 2 Stroke Trial, Recruiting NCT07307989 Sponsor: Chang Gung Memorial Hospital Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT07307989
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with an ischemic stroke (a stroke caused by a blocked blood vessel) or a TIA (a "mini-stroke" or temporary stroke-like episode)
  • People whose stroke or TIA symptoms occurred within the last 30 days, and who are able to start the assigned study medication within 2 days of being enrolled in the trial
  • People aged 20 years or older
  • People whose LDL cholesterol level (sometimes called "bad cholesterol") was measured at 100 mg/dL or higher after their stroke or TIA
  • People who have evidence of atherosclerosis (a condition where fatty deposits build up inside blood vessels)

Who may not be able to join:

  • People with end-stage kidney disease (the most severe stage of kidney failure)
  • People who have previously had a bad reaction or intolerance to statin medications (a common type of cholesterol-lowering drug)
  • People who have previously had a bad reaction or intolerance to ezetimibe (another type of cholesterol-lowering drug)
  • People whose liver enzyme levels (specifically ALT) are higher than 100 U/L, which may indicate a liver problem
  • People who were regularly taking statin medications before their stroke occurred
  • People who were taking ezetimibe before their stroke occurred

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886978233755

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
31 July 2029

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

LDL-C levels < 70 mg/dL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov